258 related articles for article (PubMed ID: 23674772)
1. MR imaging of prostate cancer in radiation oncology: what radiologists need to know.
Boonsirikamchai P; Choi S; Frank SJ; Ma J; Elsayes KM; Kaur H; Choi H
Radiographics; 2013 May; 33(3):741-61. PubMed ID: 23674772
[TBL] [Abstract][Full Text] [Related]
2. Re: MR imaging of prostate cancer in radiation oncology: what radiologists need to know.
Siegel C
J Urol; 2014 Aug; 192(2):423-4. PubMed ID: 25034994
[No Abstract] [Full Text] [Related]
3. Role of Prostate MR Imaging in Radiation Oncology.
Ménard C; Paulson E; Nyholm T; McLaughlin P; Liney G; Dirix P; van der Heide UA
Radiol Clin North Am; 2018 Mar; 56(2):319-325. PubMed ID: 29420985
[TBL] [Abstract][Full Text] [Related]
4. Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience.
Panje C; Panje T; Putora PM; Kim SK; Haile S; Aebersold DM; Plasswilm L
Radiat Oncol; 2015 Feb; 10():47. PubMed ID: 25880635
[TBL] [Abstract][Full Text] [Related]
5. Image-based brachytherapy: a forum for collaboration between radiation oncologists and diagnostic radiologists.
Erickson B
J Am Coll Radiol; 2005 Sep; 2(9):753-8. PubMed ID: 17411923
[TBL] [Abstract][Full Text] [Related]
6. Implications of CT imaging for postplan quality assessment in prostate brachytherapy.
Petrik D; Araujo C; Kim D; Halperin R; Crook JM
Brachytherapy; 2012; 11(6):435-40. PubMed ID: 22732323
[TBL] [Abstract][Full Text] [Related]
7. Tumor and normal tissue dosimetry changes during MR-guided pulsed-dose-rate (PDR) brachytherapy for cervical cancer.
Morgia M; Cuartero J; Walsh L; Jezioranski J; Keeler K; Xie J; Massey C; Williamson D; Cho YB; Oh S; Fyles A; Milosevic M
Radiother Oncol; 2013 Apr; 107(1):46-51. PubMed ID: 23540555
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance-guided adaptive radiotherapy: a solution to the future.
Kupelian P; Sonke JJ
Semin Radiat Oncol; 2014 Jul; 24(3):227-32. PubMed ID: 24931098
[TBL] [Abstract][Full Text] [Related]
9. [Advances in highly conformal radiotherapy for prostate cancer: past, current, and future].
Ishikawa H; Hashimoto T; Makishima H; Mizumoto M; Okumura T; Sakurai H
Igaku Butsuri; 2012; 32(3):138-47. PubMed ID: 24592684
[TBL] [Abstract][Full Text] [Related]
10. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy.
Al-Salihi O; Mitra A; Payne H
Prostate Cancer Prostatic Dis; 2006; 9(4):370-3. PubMed ID: 16832383
[TBL] [Abstract][Full Text] [Related]
11. The value of magnetic resonance imaging for radiotherapy planning.
Dirix P; Haustermans K; Vandecaveye V
Semin Radiat Oncol; 2014 Jul; 24(3):151-9. PubMed ID: 24931085
[TBL] [Abstract][Full Text] [Related]
12. Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy.
Roy C; Foudi F; Charton J; Jung M; Lang H; Saussine C; Jacqmin D
AJR Am J Roentgenol; 2013 Apr; 200(4):W361-8. PubMed ID: 23521479
[TBL] [Abstract][Full Text] [Related]
13. Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans.
Jani AB; Hand CM; Lujan AE; Roeske JC; Zagaja GP; Vijayakumar S; Pelizzari CA
Med Dosim; 2004; 29(1):42-8. PubMed ID: 15023392
[TBL] [Abstract][Full Text] [Related]
14. PET/CT and radiotherapy in prostate cancer.
De Jong IJ; De Haan TD; Wiegman EM; Van Den Bergh AC; Pruim J; Breeuwsma AJ
Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):543-52. PubMed ID: 20927021
[TBL] [Abstract][Full Text] [Related]
15. Pictorial review. Magnetic resonance for radiotherapy management and treatment planning in prostatic carcinoma.
Lim C; Malone SC; Avruch L; Breau RH; Flood TA; Lim M; Morash C; Quon JS; Walsh C; Schieda N
Br J Radiol; 2015 Oct; 88(1054):20150507. PubMed ID: 26279086
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
[TBL] [Abstract][Full Text] [Related]
17. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy for locally recurrent prostate cancer after radiation.
Marcus DM; Canter DJ; Jani AB; Dobbs RW; Schuster DM; Carthon BC; Rossi PJ
Can J Urol; 2012 Dec; 19(6):6534-41. PubMed ID: 23228288
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy.
Yakar D; Hambrock T; Huisman H; Hulsbergen-van de Kaa CA; van Lin E; Vergunst H; Hoeks CM; van Oort IM; Witjes JA; Barentsz JO; Fütterer JJ
Invest Radiol; 2010 Mar; 45(3):121-5. PubMed ID: 20065860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
